# Sino Biological

> Sino Biological is a VC fund in Beijing backing Biotechnology and Biopharma. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 3
- Last investment: Feb 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sino-biological-inc
- X (Twitter): https://www.twitter.com/sinobiological
- Website: http://www.sinobiological.com
- Facebook: https://www.facebook.com/sinobiological

Sino Biological is a VC fund in Beijing focused on Biotechnology and Biopharma. Sino Biological provides a comprehensive set of biological solutions, including contract biological laboratory services and biological reagents, to help their customers accelerate their life science research, drug discovery, and biological product development. Their cutting-edge state-of-the-art platform technologies and proprietary processes allowus to deliver high quality results and products at record speed. Their solutions enable our clients to expand their in-house capacity, accelerate research and development programs, and generate significant cost-savings. Five of the top ten international pharmaceutical companies have taken advantages of their advanced platforms and high-quality services to support their drug discovery and biological R&D programs.Sino Biological is a worldwide leader in recombinant protein and antibody expression using multiple platform technologies, including transient expression in mammalian cells, stable cell line expression, E. coli. fermentation, and baculovirus expression. Sino Biological is also emerging as an antibody service and diagnostic reagent provider through its creative and innovative antibody generation solutions including anti-idiotype antibody generation and IgM purification platforms.They also offer a comprehensive list of biological research solutions including research protein and antibody reagents, purification resins, enzymes, transfection reagents, and diagnostic ELISA kits. They offer high quality reagents at a significant cost saving as compared to prices at US and Europe.

## Contacts

5 contacts available for Sino Biological. Shizune tracks 3 team members at Sino Biological. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sino-biological?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Biopharma | 1 | 33% |
| Life Science | 1 | 33% |
| Pharmaceutical | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Liangzhi Xie | President and CEO | 0 | — |
| Rob Burgess | Chief Business Officer | 0 | — |
| Yang Wang | President | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bio-Link | Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. |  | Series A | Feb 21, 2024 |  |
| PhaBuilder | PhaBuilder is a platform-based & product-based company with advanced technology in synthetic biology, focusing on the transformation and engineering application of halophilic microbes.PhaBuilder was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainlyuses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. PhaBuilder currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-Germany Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve PhaBuilder's core mission of "Using microbes to change the world and build a green future". | $53.3M | Series A | Feb 02, 2023 |  |
| PhaBuilder | PhaBuilder is a platform-based & product-based company with advanced technology in synthetic biology, focusing on the transformation and engineering application of halophilic microbes.PhaBuilder was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainlyuses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. PhaBuilder currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-Germany Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve PhaBuilder's core mission of "Using microbes to change the world and build a green future". | $13.2M | Series A | Nov 04, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Agricultural Fund of China](https://shizune.co/investors/profile/agricultural-fund-of-china) — VC Fund, 1 deal together
- Asymchem Laboratories (Tianjin) — VC Fund, 1 deal together
- [Bloomage Healthcare Consumer Goods Industry Fund](https://shizune.co/investors/profile/bloomage-healthcare-consumer-goods-industry-fund) — VC Fund, 1 deal together
- [Bridge Hill Capital](https://shizune.co/investors/profile/bridge-hill-capital) — VC Fund, 1 deal together
- [Cathay Capital](https://shizune.co/investors/profile/cathaycapital) — VC Fund, 1 deal together
- Chengtong Mixed Reform — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Sino Biological invest in?

Sino Biological invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sino Biological?

Public channels for Sino Biological include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sino Biological?

The team at Sino Biological includes Liangzhi Xie (President and CEO), Rob Burgess (Chief Business Officer) and Yang Wang (President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co